CHO Plus’s participation in this joint initiative is another step toward commercializing its patented cell engineering technology
CHO Plus an early-stage innovation company developing technology to dramatically increase the productivity of cells used to manufacture therapeutic proteins and viruses, announced that it has been accepted into Blue Knight, and will receive funding to support their JLABS @ South San Francisco residency. Blue Knight is a joint initiative created between Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA). The joint initiative is dedicated to anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements with the aim to prepare for and respond to our rapidly evolving global health environment. CHO Plus technology could expand the existing manufacturing capacity for production of therapeutic proteins and vaccines thus making the company a good fit for the mission of the Blue Knight program. Through dedicated mentorship, CHO Plus will work with BARDA representatives and associates toward mutually beneficial goals.
Recommended AI News: Code Ninjas Partners with Absorb Software to Train, Increase Kid Coders
Larry Forman, CHO Plus Co-founder and CEO, commented: “It’s great that our technology has been recognized for its potential to mitigate the effects of future pandemics or other health emergencies.”
James Panek, CHO Plus COO, added: “We are grateful for the confidence the Blue Knight initiative has shown in our technology, and for the financial support. We look forward to demonstrating the substantial increase in manufacturing productivity that our technology promises to deliver.”
CHO Plus is a resident of the Johnson & Johnson Innovation – JLABS incubator in South San Francisco, CA.
Recommended AI News: Top 10 Martech Platforms Every Marketing Team Love Having in their Stack
Comments are closed.